Medtronic Marquis DR
This article was originally published in The Gray Sheet
Executive Summary
Dual-chamber implantable cardioverter defibrillator receives FDA market go-ahead, offering faster charge times, improved longevity and patient alerts compared to previous GEM ICD family offerings, the firm claims. The 36 cc device delivers 30 joules, a charge time of 7.5 seconds and lasts 7-8 years...
You may also be interested in...
Medtronic Marquis VR
Single-chamber version of the Marquis implantable cardioverter defibrillator launches Dec. 18 following FDA approval. The market-leading dual-chamber version (DR) was approved in March (1"The Gray Sheet" March 4, 2002, In Brief). The 75 g 36 cc VR features the highly specific Wavelet detectionalgorithm to distinguish significant arrhythmias from benign fluctuations in the heart's rhythm, Medtronic explains in a release...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.